Health
Neoadjuvant Dual ICI Leads to Clinical Benefit in Operable NSCLC – MedPage Today
More than one-third of patients achieved major pathologic response with nivolumab-ipilimumab.
Neoadjuvant combination immunotherapy with nivolumab (Opdivo) plus ipilimumab (Yervoy) produced a significant clinical benefit for patients with operable stage I-III non-small cell lung cancer (NSCLC), researchers reported.
The phase II NEOSTAR study randomly assigned 44 patients with operable NSCLC to neoadjuvant nivolumab with or without ipilimumab followed by surgery. Among those, 38% of patients that received the combination achieved major pathological response (MPR) — defined as 10% or less…
-
General13 hours agoWoman in her 20s dies after dog attack in Western Australia’s north
-
General19 hours agoGold Coast warned it faces traffic gridlock without major shift to public transport
-
Noosa News22 hours agoDicky Bill salad greens farms enter administration with 180 job cuts just before Christmas
-
Business24 hours ago1 unstoppable artificial intelligence (AI) stock to buy before it soars more than 300%, according to a Wall Street analyst